EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment

BlueRock begins phase 3 study of bemdaneprocel in Parkinson’s disease

Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU

Preclinical results highlight potential of glycosaminoglycan-based therapy

Data from trials highlight long-term disease control and quality of life improvements

First patient dosed in study of novel EP4 antagonist for advanced solid tumours

Durvalumab becomes first immunotherapy recommended for LS-SCLC patients in England and Wales

MHRA greenlights oral therapy for patients aged 12 and over with grade 2 astrocytoma

Positive orphan drug opinion supports SOM3355’s potential as first-line treatment in Europe

Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon